Amylyx (AMLX) Q1 2026 Earnings Call Summary

Amylyx reported $279.8 million in cash and marketable securities as of the end of Q1 2026, sufficient to fund operations through 2028. The company increased total operating expenses by 16% year-over-year due to clinical development for avexitide and an R&D milestone payment.

By Motley Fool Transcribing · Motley Fool · May 8, 2026, 15:16 UTC

Amylyx (AMLX) Q1 2026 Earnings Call Summary

Tickers: $AMLX

Topics: cash_position clinical_trials operating_expenses

Read the full article at Motley Fool

More World news

CytoDyn Secures $5 Million Private Placement for Leronlimab Development Seeking Alpha · November 12, 2026, 14:38 UTC
Cohen & Company Reports Q3 Earnings Miss on Declining Revenue and EPS Seeking Alpha · November 12, 2026, 14:39 UTC
Jensen Huang Resigns as Nvidia CEO Amid Investigation into Foreign Intelligence Allegations Motley Fool · November 12, 2026, 14:39 UTC
SuperCom Reports Q3 Fiscal 2026 Earnings Beat on Revenue and EPS Seeking Alpha · November 12, 2026, 14:35 UTC
Marvell Technology Appoints Three Independent Directors Prior to Proposed Lumentum Acquisition Seeking Alpha · November 12, 2026, 14:35 UTC
M-tron Industries Reports Q3 2026 GAAP EPS Miss Amid Low Revenue Seeking Alpha · November 12, 2026, 14:37 UTC
Nexxen International Reports Q3 Earnings Beat with Revenue Growth and Increased EBITDA Seeking Alpha · November 12, 2026, 14:30 UTC
Brookfield Corporation Announces Quarterly Dividend of $0.07 Per Share Seeking Alpha · November 12, 2026, 14:30 UTC
Upwork Expands Restructuring Plan to Reduce Workforce by 37% Seeking Alpha · November 12, 2026, 14:34 UTC
Deswell Industries Reports First-Half Revenue of $33.02 Million Amid Segment Shifts Seeking Alpha · November 12, 2026, 14:35 UTC